Blastocyst development in equine oocytes with low meiotic competence after suppression of meiosis with roscovitine prior to in vitro maturation.
This study was conducted to evaluate the in vitro development of equine oocytes with compact cumuli that had been subjected to a period of meiotic suppression with roscovitine before in vitro maturation. In experiment 1, oocytes were recovered from slaughterhouse-derived ovaries and held in M199 + 10% fetal bovine serum containing 66 microM roscovitine with or without an overlay of mineral oil in 5% CO2 in air at 38.2 degrees C for 16-18 or 24 h. No oocytes treated with roscovitine in the absence of an oil overlay for 16-18 h were maturing, compared with 2-4% of oocytes in other treatments. In experiment 2, oocytes were either fixed immediately after recovery, or were cultured for 18 h in the presence or absence of roscovitine. Oocytes cultured in the absence of roscovitine had a significantly higher rate of meiotic resumption (18%) than was found in the other two treatments (0). In experiment 3, oocytes were matured immediately or after 16-18 h culture with roscovitine. Maturation rates were similar between oocytes previously treated with roscovitine (22%) and control oocytes (19%). Mature oocytes were fertilized by intracytoplasmic sperm injection and then cultured, with or without oviductal epithelial cells, for 7.5 days. There was no significant effect of roscovitine treatment on blastocyst development. Development to blastocyst of roscovitine-treated oocytes in DMEM/F-12 + co-culture (37%) was significantly higher than that of control oocytes in DMEM/F-12 without co-culture (14%). These data indicate that equine oocytes with compact cumuli can be held in roscovitine before maturation without any harmful effect on blastocyst formation.
Choi
Y H
YH
Department of Veterinary Physiology and Pharmacology, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX 77843-4466, USA.
Love
L B
LB
Varner
D D
DD
Hinrichs
K
K
D000818:Animals; D001755:Blastocyst / Q000187:drug effects / Q000502:physiology*; D018920:Coculture Techniques; D004847:Epithelial Cells / Q000166:cytology / Q000502:physiology; D005187:Fallopian Tubes / Q000166:cytology / Q000502:physiology; D005260:Female; D006736:Horses / Q000196:embryology*; D008540:Meiosis / Q000187:drug effects*; D009865:Oocytes / Q000166:cytology / Q000187:drug effects / Q000254:growth & development*; D047428:Protein Kinase Inhibitors / Q000378:metabolism / Q000494:pharmacology; D011687:Purines / Q000378:metabolism / Q000494:pharmacology*; D000077546:Roscovitine; D020554:Sperm Injections, Intracytoplasmic
D047428:Protein Kinase Inhibitors; D011687:Purines; D000077546:Roscovitine